현재가
Klotho Neurosciences, Inc. (KLTOW) is a pioneering biotechnology company focused on leveraging the therapeutic potential of the Klotho gene to develop innovative treatments for neurodegenerative diseases and cognitive de...|
e.g. Promoter holding
Loading chart...
애널리스트 컨센서스 기준 EPS 및 매출 전망.
해당 기업의 실적 전망 데이터가 없습니다.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | JJasper The... | JSPRW | — | — | — | — | — | -255.00% | — |
| 2. | CCingulate... | CINGW | — | — | — | — | — | -198.70% | — |
| 3. | DDermata Th... | DRMAW | — | — | — | — | — | -183.90% | — |
| 4. | PProtagenic... | PTIXW | — | — | — | — | — | -513.00% | — |
| 5. | ISeaStar Me... | ICUCW | — | — | — | — | -817.00% | -356.90% | 82.00% |
연결 기준 (백만 단위) / 별도 보기 가능
| Quarter (M) | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 0.11 | 0.67 | 0.4 | 2.87 | 1.85 | 1.59 | 1.89 | 1.85 | |
EBIT | -0.11 | -0.67 | -0.4 | -2.87 | -1.85 | -1.59 | -1.89 | -1.85 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | -0.02 | 0 | -0.06 | -0.09 | -0.22 | -0.65 | -2.2 | -1.04 |
PBT | -0.13 | -0.67 | -0.45 | -2.96 | -2.07 | -2.23 | -4.09 | -2.9 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -0.13 | -0.67 | -0.45 | -2.96 | -2.07 | -2.23 | -4.09 | -2.9 |
NPM % | - | - | - | - | - | - | - | - |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 1.11 | 0.57 | 0.63 | 5.54 | |
EBIT | -1.11 | -0.57 | -0.63 | -5.54 |
OPM % | - | - | - | - |
Non-Operating Income | 0 | -0.02 | -0.08 | -0.61 |
PBT | -1.11 | -0.6 | -0.71 | -6.15 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | -1.11 | -0.6 | -0.71 | -6.15 |
NPM % | - | - | - | - |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| 0.3 | 0.08 | 0 | 0.06 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| 0 | 0.25 | 0 | 0.09 | |
| 0.74 | 2.21 | 2.19 | 2.3 | |
Total Assets | 1.04 | 2.54 | 2.19 | 2.46 |
| 0.1 | 0.86 | 0 | 0 | |
| 0.92 | 0.32 | 0.57 | 1.18 | |
| 0 | 1.35 | 1.47 | 0.27 | |
| 0.02 | 0.01 | 0.15 | 0.98 | |
| 0 | 0 | 0 | 0.02 | |
Total Liabilities | 1.04 | 2.54 | 2.19 | 2.46 |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| -0.28 | -0.6 | -0.45 | -2.95 | |
| 0 | -0.13 | 0.02 | -0.12 | |
| 0.25 | 0.5 | 0.35 | 3.13 | |
Net CFNet Cash Flow | -0.03 | -0.22 | -0.07 | 0.06 |
FCFFree Cash Flow | -0.28 | -0.72 | -0.46 | -3.07 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|
| - | -54.3% | -80.8% | -700.1% | |
| - | 1.14 | 2.57 | 0.23 | |
| 20.12 | 0.24 | 0.00 | 0.13 | |
| - | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 0.26 | 1.00 | 0.63 | 0.48 |
Payout Ratio | - | - | - | - |
| - | - | - | - | |
| -0.44 | -0.04 | -0.05 | -0.37 | |
| - | - | - | -0.18 | |
| 3.00 | 2.00 | 3.00 | 3.00 | |
| - | - | - | - | |
| 0.00 | 20.00 | 0.00 | 50.00 | |
| - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Klotho Neurosciences Inc Wt Exp의 주주 구성 (SEC 공시 기준)
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 16.89% | 13.69% | 10.21% | 4.01% | 13.81% | 8.26% | 12.73% | 12.59% | -0.14 | |
ForeignForeign institutions | 8.70% | 6.99% | 5.21% | <0.01% | 0.00% | <0.01% | 0.00% | 0.00% | 0.00 |
| 27.40% | 21.48% | 15.90% | 2.04% | 2.38% | 1.39% | 1.38% | 1.31% | -0.07 | |
Govt.Government & pensions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Public | 47.01% | 57.84% | 68.69% | 93.94% | 83.80% | 90.34% | 85.89% | 86.10% | +0.21 |
No. of institutional holders | 20 | 20 | 18 | 7 | 6 | 7 | 5 | 5 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Corporation | A1 | 1,451,268 | 9.80% | SC 13G · 10 Nov 2026 | |
| Partnership | DE | 400,410 | 8.32% | SC 13G · 3 Sep 2026 | |
| Other | DE | 6,687,472 | 5.50% | SC 13G · 13 Mar 2026 | |
| Corporation | DE | 1,621,470 | 4.99% | SC 13G/A · 2 Jul 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Month | Insiders | Shares sold | Value sold | Shares bought | Value bought | Awards, tax, gifts |
|---|---|---|---|---|---|---|
| 1 | 3,500 | $32.7K | — | — | — | |
| 1 | — | — | 14,000 | $136.1K | — | |
| 3 | — | — | 1,780,000 | $332.4K | — | |
| 1 | 175,000 | $40.3K | — | — | — | |
| 6 | — | — | — | — | 6,400,000 |
Form 4, filed within two business days of each trade. Sales and purchases are open-market; awards, tax withholding, gifts and option exercises are grouped. Amended filings are left out so a restated trade isn't counted twice.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 27 Feb 2026 | 53,905 | -8.0% | 0.04% | 9.42 | |
| 13 Feb 2026 | 58,583 | +20.2% | 0.05% | 4.72 | |
| 30 Jan 2026 | 48,745 | -0.6% | 0.04% | 4.89 | |
| 15 Jan 2026 | 49,055 | -3.5% | 0.04% | 3.65 | |
| 31 Dec 2025 | 50,836 | +6.9% | 0.04% | 2.28 | |
| 15 Dec 2025 | 47,568 | -0.4% | 0.04% | 2.60 | |
| 28 Nov 2025 | 47,777 | -6.4% | 0.04% | 5.54 | |
| 14 Nov 2025 | 51,033 | +5.2% | 0.04% | 9.62 | |
| 31 Oct 2025 | 48,525 | -10.8% | 0.04% | 3.35 | |
| 15 Oct 2025 | 54,390 | +14.9% | 0.04% | 1.01 | |
| 30 Sep 2025 | 47,317 | +32.6% | 0.04% | 1.49 | |
| 15 Sep 2025 | 35,697 | +7.0% | 0.03% | 4.10 | |
| 29 Aug 2025 | 33,364 | +4.2% | 0.03% | 3.77 | |
| 15 Aug 2025 | 32,009 | -9.3% | 0.03% | 1.34 | |
| 31 Jul 2025 | 35,289 | -21.4% | 0.03% | 1.00 | |
| 15 Jul 2025 | 44,875 | +3.9% | 0.04% | 1.00 | |
| 30 Jun 2025 | 43,192 | -71.5% | 0.04% | 1.00 | |
| 13 Jun 2025 | 151,643 | +471.7% | 0.13% | 1.00 | |
| 30 May 2025 | 26,525 | +781.2% | 0.02% | 1.00 | |
| 15 May 2025 | 3,010 | -81.6% | <0.01% | 1.00 | |
| 30 Apr 2025 | 16,319 | -3.0% | 0.01% | 3.58 | |
| 15 Apr 2025 | 16,828 | -12.4% | 0.01% | 5.79 | |
| 31 Mar 2025 | 19,202 | +36.4% | 0.02% | 2.83 | |
| 14 Mar 2025 | 14,074 | -1.1% | 0.01% | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Klotho Neurosciences Inc Wt Exp의 SEC 공시 및 실적 발표 컨퍼런스콜 녹취록
What recent news says about Klotho Neurosciences Inc Wt Exp, scored for sentiment.